Farewell to 2023, and WE are Sailing forward to 2024

Year-end Review for 2023

 

Throughout 2023, despite myriad challenges, Porton stood united, striving, and collaborating as one Team.

We are committed to developing our core CDMO business, continuously improve the EHS, Quality, and other support systems to lay a solid foundation for business development.

In May, Porton Chongqing Changshou Site and Shuitu R&D Center Passed the ISO9001, ISO14001, and ISO45001 Certifications.

In September, Porton Chongqing DP Site Passed the ISO14001 and ISO45001 Certifications.

In November, Porton Jiangxi Production Site Passed the U.S. FDA on-site Inspection.

 

Porton continuously advance the global layout, establish new capabilities, and better empower our customers.

In May, Porton New Shanghai R&D Facility was Opened for Operation.

In September, Porton Shanghai Antibody & ADC (Antibody-Drug Conjugate) R&D Center was Launched.

In September, the New Crystallization & Formulation R&D Facility of Porton USA was Opened for Operation.

Porton Continues to Push Forward with the Construction of the Slovenia GMP Manufacturing Site.

 

We maintain an open and collaborative attitude, continuously investing resources to promote brand building and create the Porton ecosystem.

 

In January, Porton Attended the J.P. Morgan Healthcare Conferences, Co-hold the Global CDMO Summit

In March, Porton Participated in DCAT Week, USA.

In June, Porton Advanced Organized The Third China Gene & Cell Therapy Innovation Forum(CGCT 2023)

In September, Porton Organized the Pharma Digital Intelligence Summit.

In October, Porton co-held the Fourth Pharma Crystallization Summit.

In October, Porton Attended 2023 CPHI Worldwide in Spain.

 

Strengthen the cooperation along the industrial supply chain and achieve win-win partnerships with industry peers.

In October, we joined hands with Merck to continuously carry out innovative collaborations in the field of antibodies and ADC (Antibody-Drug Conjugates).

In November, we established a strategic cooperation with YL-Pharma in the business of active pharmaceutical ingredients (APIs) and drug formulations.

In December, we reached a strategic cooperation with Fujian Cosunter Pharmaceutical Co, Ltd in the R&D as well as the supply chain of active pharmaceutical ingredients (APIs) and drug formulations.

 

Porton accelerates the enhancement of ESG management not only to improve our sustainable operating capabilities but also to create more environmental and social value.

• In September, Porton Completed the Establishment of an ESG Governance and Management Framework.
• In September, Porton Assessed and Identified 19 Materiality.

 

Porton Initiatives the "We Care" project of Tengyi charity activities, conveying our sincere and positive energy to society.

• In April, the "Love for Farmers" activity;
• In August, the "Build Dreams with Books" donation activity;
• In August, the "Little Chemists" activity;
• In November, the "Let Love Not Be Rare" DMD charity running activity.

And more…

 

Global recognition Spurs Porton to Continue Moving Forward.

• Porton was awarded as a National-Level Intelligent Manufacturing Demonstration Factory.
• Porton was honored as One of the Top 20 Chinese CXO Companies of 2022.
• Porton was named as one of the Top Influential CDMO Companies of 2023.
• Porton wins the 2023 Top Brands of Chinese Life Science Service Enterprise
• Porton earned Outstanding Contribution Award by Shanghai YL-Pharma
• Porton earned the Title of Best Partner of the Year 2023 by Xingsheng Xinhui.
• Porton’s S&P Global ESG score rose to 38 points.
• Porton elevated to the highest AAA level in the SZSE National Corporate ESG Rating.
• Porton received the First Guoxin Cup ESG Golden Bull Award for Top 50 Technology Leaders.
• Porton was awarded as an Outstanding Private Enterprise in Chongqing.
• Porton was recognized among the Top 100 Private Enterprises in Chongqing Municipality.